Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250861 · ClinicalTrials.gov registry record · Phase 2
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by US Oncology Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00250861 is a Phase 2 study that was terminated before completion, run by US Oncology Research. The registered enrollment target is 110 participants.
The verdict
NCT00250861, a Phase 2 study, was terminated before completion, sponsored by US Oncology Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on NHL. Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration (FDA) for the treatment of non-Hodgkins lymphoma; however, Rituximab is approved for use by itself to treat NHL.
Interventions
- DRUG Rituximab
- DRUG Aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250861
The ClinicalTrials.gov registry entry for NCT00250861 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00250861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250861 about?
NCT00250861 is a clinical study titled "Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma". The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on NHL. Rituximab and aldesleukin are...
What is the current status of trial NCT00250861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2005-10. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00250861?
The interventions under investigation include: Rituximab (DRUG), Aldesleukin (DRUG).
Who is sponsoring clinical trial NCT00250861?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.